Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol--the role of LDL-apheresis.

@article{McGowan2013EmergingLL,
  title={Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol--the role of LDL-apheresis.},
  author={Mary P. McGowan},
  journal={Journal of clinical lipidology},
  year={2013},
  volume={7 3 Suppl},
  pages={S21-6}
}
Low-density lipoprotein (LDL)-apheresis is a Food and Drug Administration-approved treatment for patients with homozygous familial hypercholesterolemia (FH) or severe heterozygous FH. Based on electrochemical principles, it selectively removes apolipoprotein B-containing lipoproteins through extracorporeal precipitation with either heparin (Heparin-induced Extracorporeal LDL Precipitation, ie, HELP) or dextran sulfate (Liposorber). LDL-apheresis can lead to an acute decrease in LDL cholesterol… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
7 Extracted Citations
24 Extracted References
Similar Papers

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 24 references

Lipoprotein apheresis

  • GR Thompson
  • Curr Opin Lipidol
  • 2010
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…